<DOC>
	<DOCNO>NCT02239276</DOCNO>
	<brief_summary>This expand access use Stiripentol Dravet Syndrome epileptic encephalopathy associate sodium channel mutation fail drug effort give best chance seizure control quality life . As treatment protocol research study , child monitor clinical basis seizure improvement side effect predominantly parent caregiver report .</brief_summary>
	<brief_title>Expanded Access Use Stiripentol Dravet Syndrome Sodium Channel Mutation Epileptic Encephalopathies</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Myoclonic</mesh_term>
	<mesh_term>Stiripentol</mesh_term>
	<criteria>6 month old Diagnosis Dravet Syndrome epileptic encephalopathy associate SCN1A mutation define : A documented gene mutation report result Dravet syndrome phenotype ; OR Clinical confirmation Dravet syndrome two pediatric neurologist ; OR Clinical confirmation epileptic encephalopathy associate sodium channel mutation Failure least 2 therapeutic anticonvulsant ( exclude Na Channel blocker ) indicative intractable seizure Hypersensitivity active substance excipients Past history psychosis form episode delirium Impaired hepatic and/or renal function , define creatinine &gt; 2 and/or transaminase &gt; 4xULN</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Stiripentol</keyword>
	<keyword>Dravet syndrome</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Epileptic Encephalopathies</keyword>
</DOC>